GENESEEQ Colon cancer test kit GENESEEQPRIME™HRD

Product catalog summary

Overview of GeneseeqHRD (PanaseeGP™)
GeneseeqHRD (PanaseeGP™) is a comprehensive genomic profiling tool designed to assess homologous recombination deficiency (HRD) in solid tumor patients. It is a CE-marked in vitro diagnostic solution that evaluates genomic instability and mutations in Homologous Recombination Repair (HRR) pathway genes to determine HRD status.

Key Features and Benefits

PARP Inhibitor Therapy Optimization: Provides a genome-wide HRD assessment to optimize the use of PARP inhibitors by detecting HRR gene alterations and evaluating genomic instability markers such as loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST).
Validated HRD Score: Offers an HRD score validated by whole genome sequencing and clinical samples to effectively match patients with PARP inhibitor therapy.
Comprehensive Coverage: Covers critical exons and translocation-related introns in 437 known actionable genes of solid tumors, aligning with guideline-recommended biomarkers.
Broad Clinical Applicability: Suitable for patients with ovarian, breast, prostate, pancreatic cancer, and other solid tumors.
Targeted Therapy Decisions: Identifies crucial genes to inform targeted treatments, including EGFR, BRAF, ALK, RET, ROS1, KRAS, ERBB2, MET, and NTRK.
Key Immunotherapy Biomarkers: Detects microsatellite instability (MSI) and calculates tumor mutational burden (TMB) using a validated algorithm.

Technical Specifications

HRR Pathway Genes: Includes genes such as BRCA1, BRCA2, ATM, RAD51, and others.
Sample Requirements: Tumor tissues in the form of FFPE slides or extracted gDNA.
Turnaround Time: Reports are expected within 5-7 days from sample receipt.
Variant Types Detected: Single nucleotide variants (SNVs), small insertion and deletion variants (indels), gene translocations, copy number variants (CNVs), MSI, and TMB.

Validation and Accreditation
GeneseeqHRD was developed as a Laboratory Developed Test (LTD) and its performance has been validated by Geneseeq Technology Inc., accredited under the College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments of 1988 (CLIA), and ISO15189:2012. The IVD version of this test has been cleared by the European Commission (CE-IVD).

Additional Services

IVD/RUO Reagent Kits for the entire NGS workflow.
Automated NGS workflow with built-in analysis solutions.
Customer service including lab space design, setup consultation, staff training, and technical support.

Catalog excerpts

GENESEEQ Colon cancer test kit GENESEEQPRIME™HRD-1

n/ GeneseeqHRD (PanaseeGP™) is a CE-marked in vitro diagnostic solution designed for evaluating homologous recombination deficiency (HRD) in solid tumor patients. This test analyzes genomic instability and mutations in Homologous Recombination Repair (HRR) pathway genes to thoroughly assess HRD status. f r PARP Inhibitor Therapy - Provides a genome-wide HRD assessment to optimize the use of PARP inhibitors. This includes: Detection of HRR gene alterations: Identifies deleterious alterations in HRR pathway genes, including both somatic and germline mutations in BRCA1/2. Genomic Instability Analysis: Evaluates HRR-related genomic instability markers such as loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST) to determine HRD status. Validated HRD score: Offers an HRD score validated by whole genome sequencing and clinical samples to effectively match patients with PARP inhibitor therapy. r Comprehensive Coverage and Broad Clinical Applicability - Covers critical exons and translocation-related introns in 437 known actionable genes of solid tumors, aligning with guideline-recommended biomarkers. Suitable for patients with ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, and other solid tumors. P Targeted Therapy Decisions Identify crucial genes to inform targeted treatments, such as EGFR, BRAF, ALK, RET, ROS1, KRAS, ERBB2, MET, and NTRK. Microsatellite Instability (MSI): Detects alterations in POLD1/POLEgenes, DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2), and microsatellite sites. Tumor Mutational Burden (TMB): allow calculation of TMB using a validated algorithm. Copyright © 2025. GENESEEQ Technology Inc. All rights reserved.

Open the catalog to page 1

GENESEEQ Colon cancer test kit GENESEEQPRIME™HRD-2

COMPREHENSIVE GENOMIC PROFILING ‘Please see sample requirement Information sheet for sample collection, storage, and shipment details. -/ Report expected in 5-7 days form sample receipt.}: Copy Numbervariants Tumor Mutational Burden(CNVs) (TMB) IVD/RUO Reagent Kits Kits contain reagents required for entire NGS workflow Customer service Lab space design & setup consultation, staff training and technical support Nucleic acid extraction Library preparation Targeted enrichment Automated NGS workflow Validated workstation adpated for NGS experiments Built-in analysis solutions GENESIS software for...

Open the catalog to page 2

All Geneseeq catalogs and technical brochures

*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.

Brand list